Celyad Oncology SA announced that Hilde Windels succeeds Michel Lussier who has been named Interim Chief Executive Officer of the Company, effective immediately. Mr. Lussier is a co-founder of the Company and has been a member of the Board of Directors since 2007. Mr. Lussier succeeds Filippo Petti who has resigned as Chief Executive Officer to pursue other opportunities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3005 EUR | -5.50% | -1.48% | -22.95% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.95% | 14.31M | |
+40.36% | 54.04B | |
+43.57% | 41.96B | |
-1.19% | 41.92B | |
-7.59% | 28.35B | |
+12.35% | 26.35B | |
-22.21% | 19B | |
+7.69% | 13B | |
+28.30% | 12.28B | |
+25.21% | 12.19B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Celyad Oncology SA Announces Chief Executive Officer Changes